Pharmaceutical giant Pfizer allegedly pressured UNICEF to agree to non-disclosure requirements on pricing that would protect information on the prices of the company’s anti-viral treatment for COVID-19 Paxlovid, sources told Geneva Health Files. UNICEF, a procurement partner for the ACT Accelerator, recently concluded a supply agreement with Pfizer for up to 4 million courses of treatment.
It is further learned that UNICEF reportedly took a unilateral decision to finalise the supply agreement with Pfizer without taking into account other partners of the therapeutics pillar of the ACT Accelerator (ACT A) including WHO, Global Fund, Unitaid. (Charitable Foundation Wellcome Trust is also a part of the therapeutics pillar of the ACT A.)
Experts point out that Pfizer has required confidentiality with respect to pricing in many of its vaccine purchase or sale agreements with international organizations and governments.
Photo by Pixabay: Pexels
To read the full story, you will need to sign up to our newsletter. We have four editions a month published every Friday.
Questions? Get in touch with us. [firstname.lastname@example.org]